Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Recurso digital |
| Language: | |
| Published: |
Zenodo
2025
|
| Online Access: | https://doi.org/10.5281/zenodo.15501007 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Table of Contents:
- <p>Antimicrobial resistance (AMR) is a major global health concern, largely driven by the excessive and improper use of antimicrobials in both medical and agricultural practices. Antibiotics are becoming increasingly popular due to their ability to promote tissue regeneration, antifungal activity, and antiviral activity. In this context, probiotics and microbiota management have emerged as promising tools to prevent infections and reduce reliance on antibiotics. This review aims to provide a brief overview of the mechanisms, brief clinical manifestations, opportunities and development. The main objective of this review is to provide an overview of antibacterial agents mechanisms and brief clinical features. The creation of new antibiotics is in progress to address the growing challenges posed by AMR. A particularly promising strategy in this field involves the creation of narrow-spectrum antibiotics: Ceftolozane-Tazobactam (Zerbaxa). Antibiotic peptides (AMPs) and peptidomimetics are gaining recognition as viable alternatives to conventional antibiotics, presenting novel strategies to combat the escalating issue of anti-AMR. ASPs can incorporate drug repurposing strategies to extend the lifespan of existing antibiotics Surveillance and Research: ASP can incorporate drugs repurposed drugs to provide immediate therapeutic options for multidrug-resistant (MDR) infections.</p>